Nexalis TherapeuticsASX:NX1 -7.69% FCF Yield % is -29.26 as of Jun. 30, 2026. The stock has 3 warning signs investors should review. Among 1,415 Biotechnology companies, Nexalis Therapeutics ranks worse than 73.22% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Nexalis Therapeutics FCF Yield % Related Terms
Nexalis Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Nexalis Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:NX1 vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Nexalis Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexalis Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nexalis Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Nexalis Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nexalis Therapeutics (ASX:NX1) has a FCF Yield % of -29.26 as of Jun. 30, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Nexalis Therapeutics and its competitors. According to the industry distribution chart, Nexalis Therapeutics ranks #1036 out of 1415 companies in the Biotechnology industry, placing it in the top 73.2%.
Is Nexalis Therapeutics' FCF Yield % too high?
Nexalis Therapeutics' current FCF Yield % is -29.26. Based on the distribution chart, Nexalis Therapeutics ranks #1036 out of 1415 companies in the Biotechnology industry, which is below the industry midpoint.
How does Nexalis Therapeutics' FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nexalis Therapeutics ranks #1036 out of 1415 companies for FCF Yield %. This places Nexalis Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Nexalis Therapeutics and its competitors. Nexalis Therapeutics's current FCF Yield % is -29.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexalis Therapeutics stock overvalued right now?
Nexalis Therapeutics (ASX:NX1) has a current FCF Yield % of -29.26. The current FCF Yield % is -29.26. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Nexalis Therapeutics (ASX:NX1), the current FCF Yield % is -29.26 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nexalis Therapeutics Ltd is an Australian clinical-stage drug development company that is focused on developing therapies to address unmet medical needs in pain management and mental health sectors. Its pipeline includes three clinical drug candidates focused on treatment-resistant depression (SRX-25), breakthrough cancer pain (IRX-211), and panic disorder (IRX-616a), each addressing areas of unmet medical need and potential commercial demand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NX1 has been successfully added to your 